Acute Severe Anticoagulation Reversal — Warfarin, DOACs & Heparin in the ICU

Your progress

Saved on this device.

Target exams

Red flags

• Life-threatening bleeding (intracerebral haemorrhage, retroperitoneal, massive GI bleed with shock) on ANY anticoagulant = REVERSE IMMEDIATELY if the history is clear — in VKA-ICH faster INR normalisation was associated with smaller haematoma expansion in the INCH trial
• WARFARIN: guideline-based reversal pairs 4F-PCC with intravenous vitamin K 10 mg — PCC replaces factors at once while vitamin K restores hepatic synthesis more slowly; giving only one component is the classic error
• DABIGATRAN bleeding → idarucizumab 5 g IV — a monoclonal antibody fragment; median maximum reversal 100 per cent within 4 h in RE-VERSE AD. Dabigatran is also removable by haemodialysis — unlike the anti-Xa agents
• RIVAROXABAN or APIXABAN bleeding → andexanet alfa (approved for life-threatening or uncontrolled bleeding) or 4F-PCC 50 IU per kg per neurocritical care guidance — thrombotic events occurred in 10 per cent at 30 days after andexanet in ANNEXA-4
• Protamine for UFH reversal: conventionally 1 mg per 100 units heparin — protamine overdose itself impairs clot formation and causes cardiovascular and pulmonary complications
• LMWH (enoxaparin) reversal with protamine is incomplete and its optimal dosing is not established — expect residual anticoagulant effect and monitor anti-Xa
• DO NOT reverse anticoagulation for minor bleeding or an isolated elevated INR without bleeding — hold the drug and use local measures, plus oral vitamin K for warfarin over-anticoagulation without bleeding
• Parenteral vitamin K1 carries a boxed warning for severe hypersensitivity reactions including fatalities with intravenous administration — it remains the sustained component of warfarin reversal
• Restarting anticoagulation after anticoagulant-associated ICH with a mechanical heart valve: restarting within less than 2 weeks was associated with increased haemorrhagic complications — earliest restart day 6, and only for high thromboembolic risk